Suppr超能文献

心力衰竭的流行病学和病因学。

Epidemiology and aetiology of heart failure.

机构信息

Division of Cardiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095, USA.

Department of Health Policy and Management, UCLA Fielding School of Public Health, 650 Charles E Young Drive South, Los Angeles, California 90095, USA.

出版信息

Nat Rev Cardiol. 2016 Jun;13(6):368-78. doi: 10.1038/nrcardio.2016.25. Epub 2016 Mar 3.

Abstract

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience numerous symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance, and fluid retention. Although the underlying causes of HF vary according to sex, age, ethnicity, comorbidities, and environment, the majority of cases remain preventable. HF is associated with increased morbidity and mortality, and confers a substantial burden to the health-care system. HF is a leading cause of hospitalization among adults and the elderly. In the USA, the total medical costs for patients with HF are expected to rise from US$20.9 billion in 2012 to $53.1 billion by 2030. Improvements in the medical management of risk factors and HF have stabilized the incidence of this disease in many countries. In this Review, we provide an overview of the latest epidemiological data on HF, and propose future directions for reducing the ever-increasing HF burden.

摘要

心力衰竭(HF)是一个迅速增长的公共卫生问题,全球估计有超过 3770 万人患有该病。HF 是一种继发于多种病因的心脏功能障碍的共同慢性阶段,HF 患者会经历许多影响其生活质量的症状,包括呼吸困难、疲劳、运动耐量差和体液潴留。尽管 HF 的根本病因因性别、年龄、种族、合并症和环境而异,但大多数病例仍然是可以预防的。HF 与发病率和死亡率的增加相关,并给医疗保健系统带来了巨大负担。HF 是成年人和老年人住院的主要原因。在美国,HF 患者的总医疗费用预计将从 2012 年的 209 亿美元增加到 2030 年的 531 亿美元。许多国家对危险因素和 HF 的医疗管理的改进稳定了该病的发病率。在这篇综述中,我们概述了 HF 的最新流行病学数据,并提出了减少不断增加的 HF 负担的未来方向。

相似文献

1
Epidemiology and aetiology of heart failure.
Nat Rev Cardiol. 2016 Jun;13(6):368-78. doi: 10.1038/nrcardio.2016.25. Epub 2016 Mar 3.
2
Prevalence and socio-economic burden of heart failure in an aging society of South Korea.
BMC Cardiovasc Disord. 2016 Nov 10;16(1):215. doi: 10.1186/s12872-016-0404-2.
3
Epidemiology and cost of advanced heart failure.
Prog Cardiovasc Dis. 2011 Sep-Oct;54(2):78-85. doi: 10.1016/j.pcad.2011.04.002.
4
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.
Circ Heart Fail. 2013 May;6(3):606-19. doi: 10.1161/HHF.0b013e318291329a. Epub 2013 Apr 24.
5
Economic burden of heart failure in the elderly.
Pharmacoeconomics. 2008;26(6):447-62. doi: 10.2165/00019053-200826060-00001.
6
Epidemiology and risk profile of heart failure.
Nat Rev Cardiol. 2011 Jan;8(1):30-41. doi: 10.1038/nrcardio.2010.165. Epub 2010 Nov 9.
8
The medical and socioeconomic burden of heart failure: A comparative delineation with cancer.
Int J Cardiol. 2016 Jan 15;203:279-81. doi: 10.1016/j.ijcard.2015.10.172. Epub 2015 Oct 20.
9
Heart failure burden and therapy.
Europace. 2009 Nov;11 Suppl 5:v1-9. doi: 10.1093/europace/eup304.
10
Epidemiology of heart failure in Asia.
Circ J. 2013;77(9):2209-17. doi: 10.1253/circj.cj-13-0971. Epub 2013 Aug 14.

引用本文的文献

1
Uncovering key biomarkers, potential therapeutic targets and development of deep learning model in heart failure.
PLoS One. 2025 Sep 3;20(9):e0330780. doi: 10.1371/journal.pone.0330780. eCollection 2025.
2
Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.
Ann Med Surg (Lond). 2025 Jul 16;87(9):5696-5719. doi: 10.1097/MS9.0000000000003592. eCollection 2025 Sep.
3
CPNE5 overexpression inhibits cardiomyocytes apoptosis by promoting the degradation of FAS receptor.
iScience. 2025 Aug 6;28(9):113302. doi: 10.1016/j.isci.2025.113302. eCollection 2025 Sep 19.
4
Effects of traditional Chinese exercises on the rehabilitation of patients with chronic heart failure: A -analysis.
Int J Cardiol Heart Vasc. 2025 Aug 20;60:101778. doi: 10.1016/j.ijcha.2025.101778. eCollection 2025 Oct.
5
Novel Drug Targets in Diastolic Heart Disease.
Int J Mol Sci. 2025 Aug 20;26(16):8055. doi: 10.3390/ijms26168055.
7
Current landscape of the immunoproteasome: implications for disease and therapy.
Cell Death Discov. 2025 Aug 25;11(1):406. doi: 10.1038/s41420-025-02698-0.
8
From mitochondria to heart: the role and challenges of mitochondrial antiviral signaling protein in cardiovascular disease.
Front Cardiovasc Med. 2025 Aug 6;12:1572559. doi: 10.3389/fcvm.2025.1572559. eCollection 2025.
10
Machine learning based insights into cardiomyopathy and heart failure research: a bibliometric analysis from 2005 to 2024.
Front Med (Lausanne). 2025 Jul 25;12:1602077. doi: 10.3389/fmed.2025.1602077. eCollection 2025.

本文引用的文献

1
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.
Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16.
3
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
N Engl J Med. 2015 Oct;373(14):1295-306. doi: 10.1056/NEJMoa1507574. Epub 2015 Sep 1.
4
Chagas' Disease.
N Engl J Med. 2015 Jul 30;373(5):456-66. doi: 10.1056/NEJMra1410150.
5
Heart failure as a general pandemic in Asia.
Eur J Heart Fail. 2015 Sep;17(9):884-92. doi: 10.1002/ejhf.319. Epub 2015 Jul 29.
8
National trends in rate of patients hospitalized for heart failure and heart failure mortality in France, 2000-2012.
Eur J Heart Fail. 2015 Jun;17(6):583-90. doi: 10.1002/ejhf.284. Epub 2015 May 6.
9
A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010.
JAMA Intern Med. 2015 Jun;175(6):996-1004. doi: 10.1001/jamainternmed.2015.0924.
10
Demographic and epidemiologic drivers of global cardiovascular mortality.
N Engl J Med. 2015 Apr 2;372(14):1333-41. doi: 10.1056/NEJMoa1406656.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验